Hui Wang

Phase II single-arm study of brentuximab vedotin in Chinese patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large cell lymphoma

Wei Li, Jun Zhu, X. Ke, 2021, Expert review of hematology.

Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study

P. Richardson, P. Moreau, Jing Liu, 2017, Journal of Hematology & Oncology.

Ixazomib plus lenalidomide-dexamethasone (IRd) vs placebo-Rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM): China continuation of TOURMALINE-MM1.

P. Richardson, P. Moreau, Jing Liu, 2016 .